RxDoctor Payments DataLook up a doctor →

Michelle Stone

Adult Health · New Brunswick, NJNPI 1093257289

Payments from drug & device makers

$7,112in general payments, 2019–2025

Across 460 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$903
  • Amgen$482
  • Boehringer Ingelheim$473
  • AstraZeneca$470
  • Vifor Pharma, Inc.$406
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,01099%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,112 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$45,264
Medicare patients
175
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide538$669,010
OzempicSemaglutide309$524,756
JardianceEmpagliflozin429$435,907
TrulicityDulaglutide260$346,163
FarxigaDapagliflozin Propanediol188$199,428
JanuviaSitagliptin Phosphate105$84,657
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog92$51,420
Tresiba Flextouch U-100Insulin Degludec93$49,941
Tresiba Flextouch U-200Insulin Degludec48$39,908
Fiasp FlextouchInsulin Aspart (Niacinamide)61$33,677
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog88$32,450
Lantus SolostarInsulin Glargine,hum.Rec.Anlog236$28,849
Bydureon BciseExenatide Microspheres30$26,959
SynjardyEmpagliflozin/Metformin Hcl23$23,258
VascepaIcosapent Ethyl39$21,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,144$1,018,746815 claims
Novo NordiskOzempic, Rybelsus$903$542,819320 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta$473$487,993480 claims
AstraZenecaFarxiga$470$199,428188 claims
MerckJanuvia, Janumet Xr$229$92,643117 claims
Johnson & JohnsonInvokana$146$16,39812 claims
BayerKerendia$298$15,66814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →